161.93 0.00 (0.00%)
After hours: 4:42PM EDT
|Bid||138.51 x 800|
|Ask||175.87 x 800|
|Day's Range||160.15 - 162.33|
|52 Week Range||128.58 - 184.00|
|PE Ratio (TTM)||22.84|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||195.00|
Below are notable corporate events for the week beginning Sept. 17. Note that this list is not comprehensive and all dates are subject to change. All times are ET. Monday Notable Earnings FedEx Corporation ...
DUBLIN , Sept. 11, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will host a webcast to provide investors with an overview of the AML treatment landscape ...
The content of this article will benefit those of you who are starting to educate yourself about investing in the stock market and want to begin learning about how toRead More...
DUBLIN , Aug. 29, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences. Wells ...
Today, the European Commission (or EC) approved the marketing authorization of Jazz Pharmaceuticals’ (JAZZ) Vyxeos. This authorization covers the treatment of adult individuals with newly diagnosed treatment-associated acute myeloid leukemia with myelodysplasia-related changes (or AML-MRC).
Jazz Pharmaceuticals' (JAZZ) Vyxeos receives marketing approval from the European Commission for treating acute myeloid leukemia.
DUBLIN, Aug. 27, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that the European Commission approved Vyxeos® 44 mg/100 mg powder for concentrate for solution for infusion for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). Vyxeos is an advanced liposomal formulation that delivers a synergistic molar ratio of daunorubicin and cytarabine.
Biotech stocks have a reputation for risk. Many more established biotech stocks exist that have built drug pipelines and revenue streams. With these pipelines and revenue streams, analysts are able to predict potential profits for years to come.
From an overall perspective, biotech stocks have enjoyed respectable gains this year. The sector exchange-traded fund SPDR S&P Biotech ETF (NYSEARCA:XBI) is up double digits since January’s opening session. That said, the market movement has been anything but steady, with several key players suffering disappointing performances.
Six years after entering the region with the acquisition of two small drug companies, Jazz Pharmaceuticals has grown to 160 employees here — or “Jazzicians” as the company likes to call its workers. On Monday, the company, after outgrowing its old space, official unveiled its new Center City 46,000-square-foot office on two floors at Commerce Square at 2005 Market St. Jazz President and COO Dan Swisher, said the company plans to add more people in Philadelphia, which is serving as its East Coast headquarters. “I wouldn’t be surprised if we are at 200 by 2020, if not sooner,” Swisher said.
Five top stocks with IBD Composite Ratings of 95 or higher are closing in on buy points: Urban Outfitters, Veeva Systems, Copart, Automatic Data Processing and Jazz Pharmaceuticals.
In its Q2 2018 earnings conference call, Endo International (ENDP) raised its 2018 adjusted EBITDA guidance from $1.2 billion–$1.3 billion to $1.27 billion–$1.33 billion. It expects its adjusted gross margin to be 68.5%–69.5%, which is higher than its previously projected range of 67%–68%. Wall Street analysts have projected Endo International’s 2018 adjusted diluted EPS at $2.50, which would be a YoY decline of 34.4%.
In the second quarter, Endo International (ENDP) reported revenues of $715 million, which is a YoY (year-over-year) decline of 18.4%. Additionally, the discontinuation of commercialization of certain generic pharmaceutical products in the US market, competitive pressures, and the divestitures of Grupo Farmacéutico Somar and Litha Healthcare Group had negative impacts on Q2 revenues. To know more about the performance of Endo International stock after its Q2 2018 earnings release, be sure to read Why Endo International Stock Soared after Q2 Results.
Are you ready? Biotech stocks provide a compelling opportunity for risk-tolerant investors looking for rich rewards. Regardless of market sentiment, economic data or trade wars, a key regulatory approval or trial data can send prices rocketing. Consider Madrigal Pharma (MDGL), which exploded by nearly 150% back in May following positive Phase 2 results for a liver-disease treatment. Of course, the opposite can also be true - prices can fall just as quickly if data or approvals fail to impress. That's why it's so crucial to conduct thorough research before investing in this high-potential (but high-risk) area of the market. For instance, using TipRanks, we can assess both the analyst consensus rating (all the stocks covered below are a "Moderate Buy" or "Strong Buy") and the expected upside potential based on recent ratings. Here are seven biotech stocks that could be catapulted higher by near-term catalysts. We'll also explore the pros' analysis and price targets for each company. SEE ALSO: The 18 Best Stocks to Buy for the Rest of 2018
In August 2018, Jazz Pharmaceuticals (JAZZ) and the University of Texas MD Anderson Cancer Center entered a five-year collaboration agreement to investigate therapies for the treatment of multiple hematologic malignancies such as AML (acute myeloid leukemia) and myelodysplastic syndrome.
Jazz Pharmaceuticals on Tuesday reported adjusted income of $3.49 per share on sales of $500 million for its second quarter.
The stock market was mildly lower early Wednesday, as China retaliated with new tariffs on U.S. goods. Michael Kors is breaking out today.
How Did Jazz Pharmaceuticals Fare in the Second Quarter? Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $356.0 million in the second quarter of 2018, which reflected ~19% year-over-year growth and ~12% sequential growth. Jazz Pharmaceuticals anticipates Xyrem’s net revenues in fiscal 2018 to be in the range of $1.87 million and $1.91 million.
On August 7, Jazz Pharmaceuticals (JAZZ) released its second-quarter 2018 financial results. Jazz Pharmaceuticals reported revenues of $500.5 million in Q2 2018 compared to $394.4 million in Q2 2017, a ~27% YoY increase and a ~13% sequential increase.